MBX Biosciences Inc
MBX30.900USD
-1.210-3.77%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM
More Details of MBX Biosciences Inc Company
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
MBX Biosciences Inc Info
Ticker SymbolMBX
Company nameMBX Biosciences Inc
IPO dateSep 13, 2024
CEOHawryluk (P. Kent Kent)
Number of employees43
Security typeOrdinary Share
Fiscal year-endSep 13
Address11711 N. Meridian Street
CityCARMEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code46032
Phone13179893100
Websitehttps://mbxbio.com/
Ticker SymbolMBX
IPO dateSep 13, 2024
CEOHawryluk (P. Kent Kent)
Company Executives of MBX Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
Ms. Ora Pescovitz, M.D.
Ms. Ora Pescovitz, M.D.
Independent Director
Independent Director
--
--
Mr. Richard B. Bartram, CPA
Mr. Richard B. Bartram, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
--
--
Mr. Edward T. (Ed) Mathers
Mr. Edward T. (Ed) Mathers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
7.02%
Other
50.46%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
7.02%
Other
50.46%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.08%
Investment Advisor/Hedge Fund
27.08%
Private Equity
23.73%
Venture Capital
12.89%
Investment Advisor
12.80%
Individual Investor
2.74%
Research Firm
0.94%
Bank and Trust
0.04%
Insurance Company
0.01%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
152
40.77M
90.80%
+4.25M
2025Q2
135
36.81M
110.11%
+2.26M
2025Q1
128
36.79M
110.24%
+3.57M
2024Q4
95
34.04M
101.87%
+3.71M
2024Q3
48
31.37M
98.32%
+31.37M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
5.22M
11.68%
-765.91K
-12.80%
Sep 26, 2025
Wellington Management Company, LLP
4.82M
10.79%
+2.56M
+112.80%
Sep 30, 2025
OrbiMed Advisors, LLC
4.00M
8.95%
--
--
Sep 26, 2025
New Enterprise Associates (NEA)
3.61M
8.09%
--
--
Jun 30, 2025
Deep Track Capital LP
2.19M
4.9%
-830.34K
-27.50%
Jun 30, 2025
Norwest Venture Partners
2.14M
4.78%
--
--
Sep 26, 2025
EcoR1 Capital, LLC
1.15M
2.57%
-109.48K
-8.69%
Jun 30, 2025
The Vanguard Group, Inc.
1.04M
2.33%
+378.12K
+56.81%
Jun 30, 2025
Driehaus Capital Management, LLC
1.57M
3.52%
-7.30K
-0.46%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.39%
iShares Health Innovation Active ETF
0.45%
ALPS Medical Breakthroughs ETF
0.32%
iShares Micro-Cap ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Russell 2000 ETF
0.02%
ProShares UltraPro Russell2000
0.02%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.39%
iShares Health Innovation Active ETF
Proportion0.45%
ALPS Medical Breakthroughs ETF
Proportion0.32%
iShares Micro-Cap ETF
Proportion0.07%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.04%
iShares Russell 2000 ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MBX Biosciences Inc?
The top five shareholders of MBX Biosciences Inc are:
Frazier Life Sciences Management, L.P. holds 5.22M shares, accounting for 11.68% of the total shares.
Wellington Management Company, LLP holds 4.82M shares, accounting for 10.79% of the total shares.
OrbiMed Advisors, LLC holds 4.00M shares, accounting for 8.95% of the total shares.
New Enterprise Associates (NEA) holds 3.61M shares, accounting for 8.09% of the total shares.
Deep Track Capital LP holds 2.19M shares, accounting for 4.90% of the total shares.
Frazier Life Sciences Management, L.P. holds 5.22M shares, accounting for 11.68% of the total shares.
Wellington Management Company, LLP holds 4.82M shares, accounting for 10.79% of the total shares.
OrbiMed Advisors, LLC holds 4.00M shares, accounting for 8.95% of the total shares.
New Enterprise Associates (NEA) holds 3.61M shares, accounting for 8.09% of the total shares.
Deep Track Capital LP holds 2.19M shares, accounting for 4.90% of the total shares.
What are the top three shareholder types of MBX Biosciences Inc?
The top three shareholder types of MBX Biosciences Inc are:
Frazier Life Sciences Management, L.P.
Wellington Management Company, LLP
OrbiMed Advisors, LLC
Frazier Life Sciences Management, L.P.
Wellington Management Company, LLP
OrbiMed Advisors, LLC
How many institutions hold shares of MBX Biosciences Inc (MBX)?
As of 2025Q3, 152 institutions hold shares of MBX Biosciences Inc, with a combined market value of approximately 40.77M, accounting for 90.80% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -19.31%.
What is the biggest source of revenue for MBX Biosciences Inc?
In --, the -- business generated the highest revenue for MBX Biosciences Inc, amounting to -- and accounting for --% of total revenue.
